Cypress Bioscience has posted a net loss of $1.8m for the second quarter 2010, or $0.05 loss per diluted share, compared to $8.61m, or $0.23 per diluted share, for the comparable period in 2009.
For the six months ended June 30, 2010, Cypress Bioscience has posted revenue of $17.24m compared to $13.66m for the year ago period.
Cypress Bioscience has further reported a net loss of $6.36m, or $0.17 per diluted share, compared to $17.77m, or $0.47 per diluted share, for the year ago period.
Cypress Bioscience is a pharmaceutical company dedicated to the development of drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system.
